Seattle Genetics Stock Rallied
Seattle Genetics (SGEN) financial results started with Clay Siegall, Ph.D., President and Chief Executive Officer of the firm stating the following:
- Seattle Genetics achieved record net sales in the U.S. and Canada for Adcetris, reflecting growth in frontline CD30-expressing peripheral T-cell lymphomas as well as frontline advanced Hodgkin lymphoma.
- The Biologics . . .
This content is for paid subscribers.